Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GC021109 in mild to moderate Alzheimer's Disease
NCT02386306Phase 1Completed
- Sponsor
- GliaCure, Inc.
- Start
- Feb 2015
- Primary completion
- Oct 2015
- Modality
- Prodrugs/Conditional Activator Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GC021109 in Alzheimer's disease (AD) (6 cohorts), sponsored by GliaCure, Inc. Primary endpoint: Treatment-Emergent Adverse Events. Started Feb 2015; status: completed.
02
Drugs
GC021109
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02386306.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02386306.